Liminatus Pharma Expands into Cryptocurrency with $500 Million BNB Investment Plan

Liminatus Pharma plans to launch a "American BNB Strategy" subsidiary to invest in BNB coin, targeting up to $500 million for long-term strategic value. The company aims to utilize custody infrastructure provided by Ceffu to ensure institutional-grade security and operational integrity. Liminatus believes this move will set a precedent for other Nasdaq-listed companies participating in the digital asset economy. The initiative remains subject to regulatory clearance and prevailing market conditions.

Liminatus Pharma, a preclinical-stage biopharmaceutical company, has announced plans to establish a subsidiary, "American BNB Strategy," to invest up to $500 million in BNB coin, the native token of the Binance ecosystem. This strategic move marks a significant departure from the company's core focus on cancer therapeutics and diagnostics, as it aims to leverage cryptocurrency for long-term growth and enhanced shareholder value.

The subsidiary, "American BNB Strategy," will focus on the strategic acquisition and long-term holding of BNB Coin. The company plans to raise capital through a planned fund, utilizing custody infrastructure provided by Ceffu to ensure institutional-grade security and operational integrity. Liminatus believes this move will set a precedent for other Nasdaq-listed companies participating in the digital asset economy.

The initiative is subject to regulatory clearance and prevailing market conditions, and the Board is currently reviewing and finalizing its approval. Liminatus CEO Chris Kim highlighted that BNB Coin was selected for its robust technology, global user base, and value-generating features such as Launchpool participation and staking models.

While Liminatus remains fully committed to its core business, the strategic pivot into cryptocurrency represents a high-risk, high-reward approach. The move could expose investors to cryptocurrency market volatility, a fundamentally different risk proposition than traditional biotech investment. However, Liminatus believes the long-term growth potential and strength of the BNB ecosystem justify this strategic shift.

The announcement follows an internal review of blockchain-integrated financial strategies conducted over the past several weeks. Liminatus is actively engaged in a capital raise process in collaboration with placement agent Digital Offering, and the initiative remains subject to regulatory clearance and market conditions.

References:
[1] https://www.stocktitan.net/news/LIMN/liminatus-pharma-inc-to-launch-american-bnb-strategy-subsidiary-and-creaj8xbkoce.html